SABSW
Price:
$0.073
Market Cap:
$28.89M
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-10-25
Stock Exchange
NASDAQ
Ticker
SABSW
According to SAB Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.25. This represents a change of -125.12% compared to the average of -1.00 of the last 4 quarters.
The mean historical PE Ratio of SAB Biotherapeutics, Inc. over the last ten years is -94.05. The current 0.25 PE Ratio has changed -126.58% with respect to the historical average. Over the past ten years (40 quarters), SABSW's PE Ratio was at its highest in in the March 2021 quarter at 75.70. The PE Ratio was at its lowest in in the December 2020 quarter at -4172.43.
Average
-94.05
Median
-1.37
Minimum
-468.57
Maximum
12.81
Discovering the peaks and valleys of SAB Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 12.81
Minimum Annual Increase = -195.55%
Minimum Annual PE Ratio = -468.57
Year | PE Ratio | Change |
---|---|---|
2023 | -0.90 | -34.28% |
2022 | -1.37 | -88.81% |
2021 | -12.24 | -195.55% |
2020 | 12.81 | -102.73% |
The current PE Ratio of SAB Biotherapeutics, Inc. (SABSW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.84
5-year avg
-94.05
10-year avg
-94.05
SAB Biotherapeutics, Inc.’s PE Ratio is greater than SAB Biotherapeutics, Inc. (-0.64), greater than Jasper Therapeutics, Inc. (-5.21), greater than NRx Pharmaceuticals, Inc. (-0.68), less than Roivant Sciences Ltd. (1.92), greater than Surrozen, Inc. (-0.66),
Company | PE Ratio | Market cap |
---|---|---|
-0.64 | $28.89M | |
-5.21 | $314.73M | |
-0.68 | $14.63M | |
1.92 | $8.60B | |
-0.66 | $27.81M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SAB Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SAB Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is SAB Biotherapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for SAB Biotherapeutics, Inc. (SABSW)?
What is the highest PE Ratio for SAB Biotherapeutics, Inc. (SABSW)?
What is the 3-year average PE Ratio for SAB Biotherapeutics, Inc. (SABSW)?
What is the 5-year average PE Ratio for SAB Biotherapeutics, Inc. (SABSW)?
How does the current PE Ratio for SAB Biotherapeutics, Inc. (SABSW) compare to its historical average?